Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal Origin

NCT03162562 is registered in ClinicalTrials.gov with CanariaBio Inc. as lead sponsor.

NCT NCT03162562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03162562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal Origin
Lead sponsor
CanariaBio Inc.
Phase
Phase 1
Overall status
Terminated
Start date
May 30, 2017
Completion date
November 5, 2020
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of ovary, neoplasms, ovarian, ovarian cancer recurrent, ovarian cancer stage iii, ovarian cancer stage iv, ovary cancer